Need Help?

Genome analysis of oesophageal cancer and Barrett's oesophagus

The median survival of oesophageal cancer this year is only 13 to 19 months after diagnosis and more than 90% will die from their disease. Therefore better treatment options are needed. The likelihood of cure for early screen-detected cancers is much higher. Barrett's oesophagus is a pre-cancerous lesion associated with a 30-40 fold increased risk of developing cancer. In an attempt to detect cancer early many patients with Barrett's are enrolled into surveillance programs involving regular endoscopies. A major problem with this approach is that the prevalence of BO in the population is estimated to be around 2%, but most patients with BO will never develop cancer. We are undertaking genomic and/or transcriptomic analysis of oesophageal tumours, Barrett's oesophagus and matched normal samples. The aim is to identify oesophageal-related genomic and transcriptomic alterations, which may reveal mutational process occurring, suggest biomarkers of tumour progression and treatment and identify novel treatment strategies.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001003996 -
EGAD00001008554 HiSeq X Ten Illumina NovaSeq 6000 44
EGAD00001008646 HiSeq X Ten 178
EGAD00001008656 Illumina HiSeq 2500 Illumina HiSeq 4000 NextSeq 2000 79
Publications Citations
Complex structural rearrangements are present in high-grade dysplastic Barrett's oesophagus samples.
BMC Med Genomics 12: 2019 31
14
ctDNA as a biomarker of progression in oesophageal adenocarcinoma.
ESMO Open 7: 2022 100452
6
Generalising uncertainty improves accuracy and safety of deep learning analytics applied to oncology.
Sci Rep 13: 2023 7395
0
Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy.
Nat Commun 14: 2023 3155
4